Object reference not set to an instance of an object. Online Stock Broker - Stock Broking, Best Share Bazaar Brokers In India
Close
  • SMC open account icon Open an A/C
    • Open an A/C
    • CHOOSE YOUR OPTION(S)
    • Trading A/c
    • Mutual Fund A/c
    • NBFC A/c
    • NPS A/c

Budget News

  • Glenmark Life Sciences IPO ends with robust subcription
  • July 30,2021  17:04
  • The initial public offer of bulk drug and contract manufacturer Glenmark Life Sciences received bids for 66.33 crore shares as against 1.50 crore shares on offer, according to stock exchange data. The issue was subscribed 44.17 times.

    The issue opened for bidding on Tuesday (27 July 2021) and closed on Thursday (29 July 2021). The price band of the IPO was fixed at Rs 695-720 per share.

    The IPO comprised of fresh issue of equity shares worth up to Rs 1,060 crore and an offer for sale of up to 63 lakh equity shares by existing shareholder Glenmark Pharmaceuticals.

    Glenmark Pharmaceuticals is the promoter of the company, which currently holds an aggregate of 10,78,04,950 equity shares, aggregating to 100% of the pre-offer issued and paid-up equity share capital. The post IPO shareholding for the same is expected to be around 82.84%.

    The proceeds from the issue will be used for payment of Rs 800 crore of outstanding purchase consideration to the Promoter Glenmark Pharmaceutical for the spin-off of the API business through business purchase agreement, funding the capital expenditure requirements of Rs 152.7 crore and remaining amount will be used for general corporate purposes.

    Ahead of the IPO, Glenmark Life Sciences on 26 July 2021 allotted 63,06,660 equity shares to 19 anchor investors, at Rs 720 per equity share, aggregating to Rs 454.07 crore.

    Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.

    The API portfolio of the company comprises of specialized and profitable products which includes niche and technically complex molecules. The company has the capacity to branch into other high value products. As of 31 December 2020, the company had a portfolio of 120 molecules globally.

    Glenmark Life Sciences reported a net profit of Rs 351.58 crore and sales of Rs 1,885.17 crore in the twelve months ended 31 March 2021.

    Powered by Capital Market - Live News

Top News
Economy News

Follow us:

  • fb icon
  • Twitter icon
  • Linkedin
  • you tube
  • Instagram

Disclaimer:

SMC Global Securities Ltd | CIN : L74899DL1994PLC063609 | Registered Office: 11/6B, Shanti Chamber, Pusa Road, Delhi-110005. | Tel +91-11-30111000 | Compliance Officer: Mr. Ashok Kumar Aggarwal | Tel 011-30111000 Extn. 170 | Email:-aka@smcindiaonline.com| Customer Care Email –smc.care@smcindiaonline.com| Complaint Email –igc@smcindiaonline.com| website: www.smctradeonline.com

SEBI Reg. No. INZ000199438, Member: NSE (07714), BSE (470), MSEI (1002), MCX (8200) & NCDEX (00021). DP SEBI Regn. No. CDSL/NSDL-IN-DP-130-2015, SMC Research Analyst Registration- INH100001849, Mutual Funds Distributor ARN No. 29345. •Insurance services are offered through SMC Insurance Brokers Pvt. Ltd. IRDAI Regn. No: DB 272/04 License No. 289 Valid upto 27/01/2026. • Real Estate Advisory services are offered through SMC Real Estate Advisors Pvt. Ltd.

Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Fund investments are subject to market risks. Read all scheme related documents carefully. PMS is not offered in commodity derivative segment. Insurance is the subject matter of solicitation. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise.

By submitting your details to SMC, you are authorizing us to send promotional communication through Call/Email/SMS/Whatsapp even though you may be registered under DND.

OUR OTHER WEBSITES Go
IMPORTANT LINKS Go
QUICK LINKS
Go

Toll-free : 1800-11-0909
Email: contact@smctradeonline.com

Sitemap
Plus Minus 
Copyright ©2016-2024 SMC. All Rights Reserved | Disclaimer | Privacy Policy | Copyright| Testimonials| Sitemap| Grievance| design agency: triverse| Powered by C-MOTS Infotech (ISO 9001:2015 certified)

Open my trading account now!  X 

* All fields are compulsory